What Makes Corcept A Stock To Watch - A Perfect Mix Of Growth, Cash, And Trial Catalysts

AI Briefing

• – Despite FDA approval for a different indication, Corcept's stock has the potential for growth due to its cash reserves and upcoming trial catalysts.
• – The company's cash balance of $234 million provides a nearly 4-year runway for further research and development.
• – The upcoming trial of Relacorilant in a secondary indication could reignite investor interest and drive stock price appreciation.